Mucalo Iva, Brajković Andrea, Strgačić Marija, Ramalho-de-Oliveira Djenane, Ribarić Elizabeta, Bobinac Ana
Centre for Applied Pharmacy, Faculty of Pharmacy and Biochemistry, University of Zagreb, 10 000 Zagreb, Croatia.
Faculty of Pharmacy and Biochemistry, University of Zagreb, 10 000 Zagreb, Croatia.
Healthcare (Basel). 2022 Apr 13;10(4):722. doi: 10.3390/healthcare10040722.
The paper aims to identify and measure the costs and savings associated with the delivery of Comprehensive Medication Management (CMM) services in Croatia in patients diagnosed with hypertension accompanied by at least one additional established cardiovascular disease (CVD) and/or type 2 diabetes mellitus (DMT2) who use five or more medicines daily. The budget impact analysis (BIA) employed in this study compares the total costs of CMM to the cost reductions expected from CMM. The cost reductions (or savings) are based on the reduced incidence of unwanted clinical events and healthcare service utilisation rates due to CMM. The BIA model is populated by data on medication therapy costs, labour, and training from the pilot CMM intervention introduced in Zagreb's main Health Centre, while relevant international published sources were used to estimate the utilisation, incidence, and unwanted clinical events rates. Total direct costs, including pharmacists' labour and training (EUR 2,667,098) and the increase in the cost of prescribed medication (EUR 5,182,864) amounted to EUR 7,849,962 for 3 years, rendering the cost per treated patient per year EUR 57. CMM is expected to reduce the utilisation rates of healthcare services and the incidence of unwanted clinical events, leading to a total 3-year reduction in healthcare costs of EUR 7,787,765. Given the total CMM costs of EUR 7,849,962, CMM's 3-year budget impact equals EUR 92,869, rendering per treated patient an incremental cost of CMM EUR 0.67. Hence, CMM appears to be an affordable intervention for addressing medication mismanagement and irrational drug use.
本文旨在识别和衡量在克罗地亚为每日使用五种或更多药物、被诊断为高血压并伴有至少一种其他已确诊心血管疾病(CVD)和/或2型糖尿病(DMT2)的患者提供综合药物管理(CMM)服务所产生的成本和节省情况。本研究采用的预算影响分析(BIA)将CMM的总成本与CMM预期的成本降低进行比较。成本降低(或节省)基于CMM导致的不良临床事件发生率降低和医疗服务利用率降低。BIA模型的数据来自萨格勒布主要健康中心引入的CMM试点干预中的药物治疗成本、劳动力和培训数据,同时使用相关国际已发表资料来估计利用率、发生率和不良临床事件发生率。3年的总直接成本,包括药剂师的劳动力和培训(2,667,098欧元)以及处方药成本的增加(5,182,864欧元),总计7,849,962欧元,使每位接受治疗的患者每年的成本为57欧元。预计CMM将降低医疗服务利用率和不良临床事件发生率,从而使3年的医疗总成本降低7,787,765欧元。鉴于CMM的总成本为7,849,962欧元,CMM的3年预算影响为92,869欧元,每位接受治疗的患者CMM的增量成本为0.67欧元。因此,CMM似乎是一种可负担得起的干预措施,用于解决药物管理不善和不合理用药问题。